PMID- 33999200
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20231213
IS  - 1460-2385 (Electronic)
IS  - 0931-0509 (Print)
IS  - 0931-0509 (Linking)
VI  - 36
IP  - 9
DP  - 2021 Aug 27
TI  - Haemodialysis patients show a highly diminished antibody response after COVID-19 
      mRNA vaccination compared with healthy controls.
PG  - 1709-1716
LID - 10.1093/ndt/gfab179 [doi]
LID - gfab179
AB  - BACKGROUND: Haemodialysis (HD) patients are exposed to a high risk due to the 
      severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. They are 
      prone to acquiring the infection and are threatened by high mortality rates in 
      case of infection. However, HD patients were not included in the efficacy trials 
      of the SARS-CoV-2 vaccines. Such efficacy data would have been critical because 
      HD patients show decreased responses against various other vaccines and this 
      could translate to the SARS-CoV-2 vaccines as well. METHODS: We conducted a 
      prospective cohort study that contained a group of 81 HD patients and 80 healthy 
      controls. All of them had been vaccinated with the BioNTech/Pfizer mRNA vaccine 
      (two doses, as per the manufacturer's recommendation). The anti-SARS-CoV-2 spike 
      (S) antibody response was measured for all participants 21 days after the second 
      dose. The groups were compared using univariate quantile regressions and a 
      multivariate analysis. The adverse events (AEs) of the vaccination were assessed 
      via a questionnaire. Finally, a correlation between the HBs-antibody response and 
      the SARS-CoV-2 antibody response in the HD patients was established. RESULTS: The 
      HD patients had significantly lower anti-SARS-CoV-2 S antibody titres than the 
      control patients 21 days after vaccination (median was 171 U/mL for dialysis 
      patients and 2500 U/mL for the controls). Further, the HD group presented fewer 
      AEs than the control group. No correlation was found between the antibody 
      response to previous Hepatitis B vaccination and that of the SARS-CoV-2 vaccine. 
      CONCLUSIONS: HD patients present highly diminished SARS-CoV-2 S antibody titres 
      compared with a cohort of controls. Therefore, they could be much less protected 
      by SARS-CoV-2 mRNA vaccinations than expected. Further studies to test 
      alternative vaccination schemes should be considered.
CI  - (c) The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA. 
      All rights reserved.
FAU - Simon, Benedikt
AU  - Simon B
AD  - Mistelbach-Ganserndorf State Clinic, Institute for Medical-Chemical Laboratory 
      Diagnostics, Mistelbach, Austria.
FAU - Rubey, Harald
AU  - Rubey H
AD  - Mistelbach-Ganserndorf State Clinic, Institute for Medical-Chemical Laboratory 
      Diagnostics, Mistelbach, Austria.
FAU - Treipl, Andreas
AU  - Treipl A
AD  - Department for Internal Medicine III-Nephrology and Diabetology, 
      Mistelbach-Ganserndorf State Clinic, Mistelbach, Austria.
FAU - Gromann, Martin
AU  - Gromann M
AD  - Department for Internal Medicine III-Nephrology and Diabetology, 
      Mistelbach-Ganserndorf State Clinic, Mistelbach, Austria.
FAU - Hemedi, Boris
AU  - Hemedi B
AD  - Department for Internal Medicine, Hainburg State Clinic, Hainburg, Austria.
FAU - Zehetmayer, Sonja
AU  - Zehetmayer S
AD  - MedUni Wien, Center for Medical Statistics, Informatics and Intelligent Systems 
      (Institute of Medical Statistics),Vienna, Austria.
FAU - Kirsch, Bernhard
AU  - Kirsch B
AD  - Department for Internal Medicine III-Nephrology and Diabetology, 
      Mistelbach-Ganserndorf State Clinic, Mistelbach, Austria.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nephrol Dial Transplant
JT  - Nephrology, dialysis, transplantation : official publication of the European 
      Dialysis and Transplant Association - European Renal Association
JID - 8706402
RN  - 0 (Antibodies, Viral)
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Vaccines, Synthetic)
SB  - IM
MH  - Antibodies, Viral/blood
MH  - *Antibody Formation
MH  - *COVID-19/prevention & control
MH  - *COVID-19 Vaccines/immunology
MH  - Humans
MH  - *Immunogenicity, Vaccine
MH  - Prospective Studies
MH  - *Renal Dialysis
MH  - Vaccination
MH  - Vaccines, Synthetic/immunology
MH  - mRNA Vaccines
PMC - PMC8194560
OTO - NOTNLM
OT  - SARS-CoV-2
OT  - antibodies
OT  - dialysis
OT  - vaccination
EDAT- 2021/05/18 06:00
MHDA- 2021/10/29 06:00
PMCR- 2021/06/11
CRDT- 2021/05/17 12:40
PHST- 2021/03/26 00:00 [received]
PHST- 2021/05/12 00:00 [accepted]
PHST- 2021/05/18 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2021/05/17 12:40 [entrez]
PHST- 2021/06/11 00:00 [pmc-release]
AID - 6276880 [pii]
AID - gfab179 [pii]
AID - 10.1093/ndt/gfab179 [doi]
PST - ppublish
SO  - Nephrol Dial Transplant. 2021 Aug 27;36(9):1709-1716. doi: 10.1093/ndt/gfab179.